UA106877C2 - Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення - Google Patents

Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення

Info

Publication number
UA106877C2
UA106877C2 UAA201103384A UAA201103384A UA106877C2 UA 106877 C2 UA106877 C2 UA 106877C2 UA A201103384 A UAA201103384 A UA A201103384A UA A201103384 A UAA201103384 A UA A201103384A UA 106877 C2 UA106877 C2 UA 106877C2
Authority
UA
Ukraine
Prior art keywords
entacapone
salts
pharmaceutical composition
extended release
release pharmaceutical
Prior art date
Application number
UAA201103384A
Other languages
English (en)
Russian (ru)
Inventor
Рітеш Капур
Муніш Талвар
Санджай МАТЕ
Манодж МАШАЛКАР
Гіріш Кумар Джаін
Мандар КОДГУЛЕ
Original Assignee
Вокхардт Рісерч Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41279194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA106877(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вокхардт Рісерч Сентер filed Critical Вокхардт Рісерч Сентер
Publication of UA106877C2 publication Critical patent/UA106877C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується фармацевтичної композиції пролонгованого вивільнення, що містить від приблизно 200 до приблизно 1000 мг ентакапону або його солей, при цьому ентакапон покритий одним або декількома гідрофільними або гідрофобними полімерами або впроваджений в матрицю, яка містить один або декілька гідрофільних або гідрофобних полімерів для досягнення пролонгованого вивільнення, необов'язково з іншими фармацевтично прийнятними ексципієнтами, та способу її отримання.
UAA201103384A 2008-08-22 2009-08-22 Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення UA106877C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1777MU2008 2008-08-22
IN1778MU2008 2008-08-22
PCT/IB2009/053698 WO2010020969A1 (en) 2008-08-22 2009-08-22 An extended release pharmaceutical composition of entacapone or salts thereof

Publications (1)

Publication Number Publication Date
UA106877C2 true UA106877C2 (uk) 2014-10-27

Family

ID=41279194

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201103384A UA106877C2 (uk) 2008-08-22 2009-08-22 Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення

Country Status (15)

Country Link
US (2) US9289392B2 (uk)
EP (1) EP2328565B1 (uk)
KR (1) KR101667762B1 (uk)
CN (1) CN102170870A (uk)
AU (1) AU2009283813B2 (uk)
BR (1) BRPI0916922A2 (uk)
CA (1) CA2734972C (uk)
ES (1) ES2476765T3 (uk)
IL (1) IL211344A0 (uk)
MX (1) MX2011002017A (uk)
NZ (1) NZ591326A (uk)
RU (1) RU2540465C2 (uk)
UA (1) UA106877C2 (uk)
WO (1) WO2010020969A1 (uk)
ZA (1) ZA201101439B (uk)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
CA2833443C (en) * 2011-04-26 2017-11-07 Innopharmax, Inc. A composition of entacapone
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
CN103845317B (zh) * 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
US9642810B2 (en) * 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
BR112020017422A2 (pt) * 2018-03-29 2020-12-22 Avion Pharmaceuticals , Llc Composição de dose fracionada de levodopa e uso

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
PL1896006T3 (pl) * 2005-06-08 2010-03-31 Orion Corp Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego
AR055106A1 (es) 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
CA2635313C (en) 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
US8741342B2 (en) * 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
EP2252284B1 (en) 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability

Also Published As

Publication number Publication date
US20110229561A1 (en) 2011-09-22
RU2540465C2 (ru) 2015-02-10
NZ591326A (en) 2012-12-21
ZA201101439B (en) 2012-04-25
BRPI0916922A2 (pt) 2015-11-24
CA2734972A1 (en) 2010-02-25
WO2010020969A1 (en) 2010-02-25
AU2009283813B2 (en) 2015-02-19
EP2328565A1 (en) 2011-06-08
US9289392B2 (en) 2016-03-22
CA2734972C (en) 2017-03-28
KR101667762B1 (ko) 2016-10-20
CN102170870A (zh) 2011-08-31
RU2011110765A (ru) 2012-09-27
MX2011002017A (es) 2011-05-19
AU2009283813A1 (en) 2010-02-25
IL211344A0 (en) 2011-05-31
ES2476765T3 (es) 2014-07-15
EP2328565B1 (en) 2014-06-04
KR20110046554A (ko) 2011-05-04
US20160015645A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
UA106877C2 (uk) Фармацевтична композиція ентакапону або його солей пролонгованого вивільнення
WO2008053297A3 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
ZA201005615B (en) Pharmaceutical compositions of entacapone,levodopa and carbidopa with improved bioavailability
MX2010014234A (es) Compuestos pirazol 436.
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
MX2009012030A (es) Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento.
EP3626253A3 (en) Stable formulations of linaclotide
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
MX2008001711A (es) Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa.
BRPI0914225A8 (pt) Método de preparação de uma composição farmacêutica de formas galênicas de liberação controlada de relaxantes do músculo-esquelético
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
ZA201003380B (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and methhod for the preparation thereof
UA101627C2 (uk) Покривна композиція, що містить полідекстрозу, спосіб її одержання і застосування для нанесення покриття на тверді форми для перорального прийому
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2010029571A3 (en) Modified release ramipril compositions and uses thereof
WO2010023473A3 (en) Crystalline form of sunitinib and processes for its preparation
UA104281C2 (uk) Протипухлинні аналоги пептидів, спосіб їх одержання та фармацевтична композиція на їх основі
WO2020068657A8 (en) 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
PH12013501900A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
WO2011121607A3 (en) Rasagiline and its pharmaceutically acceptable salts
WO2008057464A3 (en) Compositions and methods for improving the bioavailability of liothyronine
TW200727892A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same